Compare Stocks: IGXT, NRXP, VXRT, and VTVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IGXT IntelGenx Technologies	$0.17	$0.17	$0.09 ▼ $0.22	$29.17M	2.47	N/A	N/A
NRXP NRx Pharmaceuticals	$2.59 -4.1%	$3.26	$1.62 ▼ $5.05	$112.15M	2.07	1.05 million shs	695,584 shs
VTVT vTv Therapeutics	$27.52 -2.5%	$31.90	$19.50 ▼ $44.00	$108.43M	0.21	53,526 shs	20,139 shs
VXRT Vaxart	$0.46 +0.2%	$0.49	$0.31 ▼ $0.84	$111.49M	1.05	488,401 shs	217,910 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IGXT IntelGenx Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
NRXP NRx Pharmaceuticals	-5.26%	-8.16%	-20.59%	-39.46%	-13.46%
VTVT vTv Therapeutics	-7.32%	-5.99%	-11.70%	-13.64%	+29.44%
VXRT Vaxart	+3.80%	+4.65%	-5.86%	-13.85%	+34.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IGXT IntelGenx Technologies	$0.17	$0.17	$0.09 ▼ $0.22	$29.17M	2.47	N/A	N/A
NRXP NRx Pharmaceuticals	$2.59 -4.1%	$3.26	$1.62 ▼ $5.05	$112.15M	2.07	1.05 million shs	695,584 shs
VTVT vTv Therapeutics	$27.52 -2.5%	$31.90	$19.50 ▼ $44.00	$108.43M	0.21	53,526 shs	20,139 shs
VXRT Vaxart	$0.46 +0.2%	$0.49	$0.31 ▼ $0.84	$111.49M	1.05	488,401 shs	217,910 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IGXT IntelGenx Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
NRXP NRx Pharmaceuticals	-5.26%	-8.16%	-20.59%	-39.46%	-13.46%
VTVT vTv Therapeutics	-7.32%	-5.99%	-11.70%	-13.64%	+29.44%
VXRT Vaxart	+3.80%	+4.65%	-5.86%	-13.85%	+34.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IGXT IntelGenx Technologies	0.00	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	2.43	Hold	$34.50	1,232.05% Upside
VTVT vTv Therapeutics	2.78	Moderate Buy	$55.83	102.88% Upside
VXRT Vaxart	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest IGXT, NRXP, VXRT, and VTVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2026	VTVT vTv Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$57.00
9/14/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00
9/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
9/2/2026	VTVT vTv Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
8/26/2026	NRXP NRx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/26/2026	NRXP NRx Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
8/25/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/18/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00
8/11/2026	VTVT vTv Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D+) ➝ Sell (D-)
8/10/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/7/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$10.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IGXT IntelGenx Technologies	$1.04M	28.05	N/A	N/A	($0.07) per share	-2.39
NRXP NRx Pharmaceuticals	$1.23M	91.18	N/A	N/A	($0.54) per share	-4.80
VTVT vTv Therapeutics	$1.02M	106.30	N/A	N/A	$16.36 per share	1.68
VXRT Vaxart	$237.26M	0.47	$0.11 per share	4.30	$0.37 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IGXT IntelGenx Technologies	-$9.93M	-$0.06	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	-$28.62M	-$0.55	N/A	N/A	N/A	-691.81%	N/A	-63.92%	11/13/2026 (Estimated)
VTVT vTv Therapeutics	-$26.97M	-$1.06	N/A	N/A	N/A	N/A	-6.27%	-5.06%	11/5/2026 (Estimated)
VXRT Vaxart	$16.33M	$0.16	2.86	N/A	N/A	15.88%	53.04%	20.85%	11/12/2026 (Estimated)

Latest IGXT, NRXP, VXRT, and VTVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	VTVT vTv Therapeutics	-$1.16	N/A	N/A	N/A	$0.33 million	N/A
8/14/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.1067	-$0.44	-$0.3333	-$0.44	$1.33 million	$1.10 million
8/6/2026	Q2 2026	VTVT vTv Therapeutics	-$0.97	-$1.05	-$0.08	-$1.05	$0.33 million	N/A
8/6/2026	Q2 2026	VXRT Vaxart	-$0.12	-$0.06	+$0.06	-$0.06	$26.21 million	$27.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IGXT IntelGenx Technologies	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	0.86	0.86
VTVT vTv Therapeutics	N/A	12.48	12.48
VXRT Vaxart	N/A	1.60	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IGXT IntelGenx Technologies	N/A
NRXP NRx Pharmaceuticals	4.27%
VTVT vTv Therapeutics	17.51%
VXRT Vaxart	18.05%

Insider Ownership

Company	Insider Ownership
IGXT IntelGenx Technologies	42.05%
NRXP NRx Pharmaceuticals	6.40%
VTVT vTv Therapeutics	5.99%
VXRT Vaxart	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IGXT IntelGenx Technologies	38	174.66 million	101.21 million	Not Optionable
NRXP NRx Pharmaceuticals	29	43.30 million	40.53 million	Optionable
VTVT vTv Therapeutics	26	3.94 million	3.70 million	Not Optionable
VXRT Vaxart	65	243.70 million	236.88 million	No Data

IGXT, NRXP, VXRT, and VTVT Headlines

Recent News About These Companies

Analyzing Vaxart (OTCMKTS:VXRT) and Contineum Therapeutics (NASDAQ:CTNM)

October 13 at 8:17 AM | americanbankingnews.com

Vaxart (OTCMKTS:VXRT) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?

October 9, 2026 | americanbankingnews.com

Vaxart's VXA-H5-02 Shows 100% Survival In H5N1 Ferret Study

October 8, 2026 | rttnews.com

Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model

October 8, 2026 | finance.yahoo.com

Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model

October 8, 2026 | globenewswire.com

Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference

September 15, 2026 | marketbeat.com

Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | finance.yahoo.com

Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | globenewswire.com

Vaxart Secures New European Patent Covering Oral Norovirus Vaccine Technology

August 27, 2026 | finance.yahoo.com

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

August 26, 2026 | globenewswire.com

Vaxart Inc (VXRT) (Q2 2026) Earnings Call Highlights: Oral COVID Vaccine Shows Promise, Cash ...

August 10, 2026 | finance.yahoo.com

Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding

August 8, 2026 | seekingalpha.com

Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results

August 6, 2026 | markets.businessinsider.com

Vaxart Q2 2026 earnings preview

August 5, 2026 | msn.com

Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET

July 30, 2026 | finance.yahoo.com

Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET

July 30, 2026 | globenewswire.com

Vaxart to Participate in BTIG Biotechnology Conference 2026

July 21, 2026 | finance.yahoo.com

Vaxart to Participate in BTIG Biotechnology Conference 2026

July 21, 2026 | globenewswire.com

Vaxart Announces Results of Annual Meeting of Stockholders

July 17, 2026 | finance.yahoo.com

Vaxart Announces Results of Annual Meeting of Stockholders

July 17, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGXT, NRXP, VXRT, and VTVT Company Descriptions

IntelGenx Technologies OTCMKTS:IGXT

$0.17 0.00 (0.00%)

As of 10/13/2026

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

NRx Pharmaceuticals NASDAQ:NRXP

$2.59 -0.11 (-4.07%)

Closing price 04:00 PM Eastern

Extended Trading

$2.60 +0.01 (+0.39%)

As of 07:30 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

vTv Therapeutics NASDAQ:VTVT

$27.52 -0.71 (-2.52%)

Closing price 04:00 PM Eastern

Extended Trading

$27.52 0.00 (0.00%)

As of 07:30 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Vaxart OTCMKTS:VXRT

$0.46 +0.00 (+0.20%)

As of 03:49 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IGXT, NRXP, VXRT, and VTVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IGXT, NRXP, VXRT, and VTVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IGXT, NRXP, VXRT, and VTVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGXT, NRXP, VXRT, and VTVT Company Descriptions

IntelGenx Technologies OTCMKTS:IGXT

NRx Pharmaceuticals NASDAQ:NRXP

vTv Therapeutics NASDAQ:VTVT

Vaxart OTCMKTS:VXRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IGXT, NRXP, VXRT, and VTVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IGXT, NRXP, VXRT, and VTVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IGXT, NRXP, VXRT, and VTVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGXT, NRXP, VXRT, and VTVT Company Descriptions

IntelGenx Technologies OTCMKTS:IGXT

NRx Pharmaceuticals NASDAQ:NRXP

vTv Therapeutics NASDAQ:VTVT

Vaxart OTCMKTS:VXRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools